Gilead-backed Kyverna Therapeutics aims for $857.3 mln valuation in upsized IPO

Kyverna Therapeutics expects up to $857.3 million valuation in its U.S. initial public offering (IPO), the biotechnology company said on Tuesday as it raised its offering.